Articles related to ANTIDEPRESSANTS
How Durable are Responses to Novel Antidepressant Zuranolone in MDD?
In the phase III trial for zuranolone, 67.4% of patients who received an initial 2-week course at the 30-mg dose level initially achieved a 50% or greater reduction from baseline on the HAMD-17. Over the following year, half of those patients required additional 2-week courses of therapy. Of the group who received the 50-mg dose, only 25% needed subsequent courses.
Neurology October 3rd 2022
Response to Acute Monotherapy for Major Depressive Disorder in Randomized, Placebo Controlled Trials Submitted to the US Food and Drug Administration: Individual Participant Data Analysis
Study: This meta-analysis includes 232 randomized, double-blind, placebo-controlled trials of drug monotherapy for major depressive disorder submitted to the FDA between 1979 and 2016, and comprises nearly 75,000 adult and child participants. Conclusion: Patients with depression are likely to improve substantially from acute treatment of their depression with drug or placebo. Although the mean effect of antidepressants is only a small improvement over placebo, the effect of active drug seems to increase the probability that any patient will benefit substantially from treatment by about 15%.
Psychiatry August 8th 2022
“No Convincing Evidence” That Depression is Caused by Low Serotonin Levels, Say Study Authors
The idea that depression is brought on by decreased serotonin activity or concentrations is unsupported, according to the authors of a systematic umbrella review, who also challenge the rationale behind the high rates of antidepressant prescription. They claim that certain medical professionals continue to promote the incorrect chemical imbalance explanation of depression, and the public as a whole still accepts it. However, other medical professionals argue that antidepressants continue to be a helpful treatment option for patients in addition to other methods like talking therapy and that the idea that depression is caused by a straightforward chemical imbalance is outdated in any case.
Psychiatry July 26th 2022
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial
Selecting effective antidepressants for the treatment of major depressive disorder is an imprecise practice. With remission rates of about 30% after the initial therapy selection, there is a need to uncover biomarkers able to predict treatment response. This study looked at pharmacogenomic testing for drug-gene interactions to guide treatment selection. Unfortunately, they did not find significantly improved outcomes.
Psychiatry July 19th 2022
Modifying Treatment Strategies to Address Poor Response in Major Depressive Disorder
In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.
Psychiatry July 5th 2022
Meta-Analysis of Suicidality in Placebo-Controlled Clinical Trials of Adults Taking Bupropion
A new case study that analyzed the correlation between the use of antidepressants and suicide concluded that all patients treated with antidepressants should receive careful monitoring for clinical worsening, suicidality, or unusual changes in behavior.
Psychiatry May 10th 2022